John L Frater

Summary

Country: USA

Publications

  1. ncbi Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage
    John L Frater
    Department of Pathology, Northwestern Memorial Hospital and Northwestern University Medical School, Chicago, IL 60611, USA
    Arch Pathol Lab Med 127:356-9. 2003
  2. ncbi Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case
    John L Frater
    Department of Pathology, St. Louis University School of Medicine, MO 63104, and Department of Internal Medicine, Michael Reece Hospital, Chicago, IL, USA
    J Cutan Med Surg 10:281-90. 2006
  3. ncbi Histiocytic sarcoma with secondary involvement of the skin and expression of CD1a: evidence of indeterminate cell differentiation?
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    J Cutan Pathol 33:437-42. 2006
  4. ncbi Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with inv(16)(p13q22) as a sole genetic abnormality
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, 1402 South Grant Blvd, St Louis, MO 63104, USA
    Cancer Genet Cytogenet 174:161-5. 2007
  5. ncbi Lymphoblastic leukemia with mature B-cell phenotype in infancy
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA
    J Pediatr Hematol Oncol 26:672-7. 2004
  6. ncbi Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    John L Frater
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA
    Diagn Pathol 3:16. 2008
  7. ncbi Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status
    John L Frater
    Department of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Am J Clin Pathol 119:833-41. 2003
  8. ncbi Deletion of MYC and presence of double minutes with MYC amplification in a morphologic acute promyelocytic leukemia-like case lacking RARA rearrangement: could early exclusion of double-minute chromosomes be a prognostic factor?
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, Health Sciences Center, MO 63104 1095, USA
    Cancer Genet Cytogenet 166:139-45. 2006
  9. ncbi Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
    Simrit Parmar
    Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St. Clair Street, Suite 850, Chicago, IL 60611, USA
    Leuk Res 28:909-19. 2004
  10. ncbi Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients
    Richard A Prayson
    Department of Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Clin Pathol 117:776-82. 2002

Detail Information

Publications10

  1. ncbi Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage
    John L Frater
    Department of Pathology, Northwestern Memorial Hospital and Northwestern University Medical School, Chicago, IL 60611, USA
    Arch Pathol Lab Med 127:356-9. 2003
    ..We describe an unusual case of acute leukemia meeting the criteria for biphenotypic acute leukemia in which CD79a expression was observed in the blast population...
  2. ncbi Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case
    John L Frater
    Department of Pathology, St. Louis University School of Medicine, MO 63104, and Department of Internal Medicine, Michael Reece Hospital, Chicago, IL, USA
    J Cutan Med Surg 10:281-90. 2006
    ..Compared with patients with systemic Rosai-Dorfman disease, patients with primary cutaneous Rosai-Dorfman disease are older, women are more commonly affected, and whites are more likely than blacks to be afflicted...
  3. ncbi Histiocytic sarcoma with secondary involvement of the skin and expression of CD1a: evidence of indeterminate cell differentiation?
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    J Cutan Pathol 33:437-42. 2006
    ....
  4. ncbi Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with inv(16)(p13q22) as a sole genetic abnormality
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, 1402 South Grant Blvd, St Louis, MO 63104, USA
    Cancer Genet Cytogenet 174:161-5. 2007
    ..We review the literature and discuss the possible role of this genetic lesion in B-cell neoplasia...
  5. ncbi Lymphoblastic leukemia with mature B-cell phenotype in infancy
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA
    J Pediatr Hematol Oncol 26:672-7. 2004
    ..The authors describe an infant with mature B-cell lymphoblastic leukemia with an mll rearrangement and L1/L2 cytomorphology and discuss the clinical, genetic, and immunophenotypic features in the context of previously reported cases...
  6. ncbi Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    John L Frater
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA
    Diagn Pathol 3:16. 2008
    ..The extent of enhanced bone marrow angiogenesis in chronic lymphocytic leukemia (CLL) and relationship to proangiogenic factors and prognostic indicators is largely unexplored...
  7. ncbi Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status
    John L Frater
    Department of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Am J Clin Pathol 119:833-41. 2003
    ..Although all patients demonstrated an initial decrease in bone marrow cellularity after imatinib mesylate therapy, continued follow-up showed that histopathologic findings correlated with genetic response...
  8. ncbi Deletion of MYC and presence of double minutes with MYC amplification in a morphologic acute promyelocytic leukemia-like case lacking RARA rearrangement: could early exclusion of double-minute chromosomes be a prognostic factor?
    John L Frater
    Department of Pathology, Saint Louis University School of Medicine, Health Sciences Center, MO 63104 1095, USA
    Cancer Genet Cytogenet 166:139-45. 2006
    ..Excessive exclusion of dmin was observed at the initial diagnosis. These findings are compared to the few cases previously reported in the literature...
  9. ncbi Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
    Simrit Parmar
    Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St. Clair Street, Suite 850, Chicago, IL 60611, USA
    Leuk Res 28:909-19. 2004
    ..All subjects had progressive disease. There was no direct treatment-related mortality. Based on this study, we do not recommend single agent ATO as a treatment option for AML...
  10. ncbi Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients
    Richard A Prayson
    Department of Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Clin Pathol 117:776-82. 2002
    ..The pathologicfindings may be only focally present, and missed, if diagnosis is made or confirmed with biopsy alone. Most lymphoid cells have a T-cell immunophenotype, with a predominance of CD8+ cells in most cases...